| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2024 | CRI BIOTECH, INC | 24133 YOUNG CT | LOS ALTOS | CA | 94024-5231 | SANTA CLARA | USA | R44HL167349 | RSK3 Anchoring Disruptor Therapy for Heart Failure | 000 | 2 | NIH | 2/21/2025 | -$1,227,614 |
| | 2025 | 2024 | CRI BIOTECH, INC | 24133 YOUNG CT | LOS ALTOS | CA | 94024-5231 | SANTA CLARA | USA | R44HL167349 | RSK3 Anchoring Disruptor Therapy for Heart Failure | 001 | 2 | NIH | 2/26/2025 | $1,227,614 |
|
| Issue Date FY: 2024 ( Subtotal = $1,982,787 ) |
| | 2024 | 2024 | CARDIAC RSK3 INHIBITORS LLC | 24133 YOUNG CT | LOS ALTOS | CA | 94024-5231 | SANTA CLARA | USA | R44HL167349 | RSK3 Anchoring Disruptor Therapy for Heart Failure | 001 | 2 | NIH | 7/15/2024 | $1,982,787 |
| | 2024 | 2023 | CARDIAC RSK3 INHIBITORS, LLC | 24133 YOUNG COURT | LOS ALTOS | CA | 94024-5231 | SANTA CLARA | USA | R44HL167349 | RSK3 Anchoring Disruptor Therapy for Heart Failure | 000 | 1 | NIH | 10/19/2023 | $0 |
| | 2024 | 2022 | CRI BIOTECH, INC | 24133 YOUNG CT | LOS ALTOS | CA | 94024-5231 | SANTA CLARA | USA | R44HL147631 | ShRNA-Based Targeting of mAKAPβ in Heart Failure | 000 | 3 | NIH | 7/11/2024 | $0 |
| | 2024 | 2021 | CRI BIOTECH, INC | 24133 YOUNG CT | LOS ALTOS | CA | 94024-5231 | SANTA CLARA | USA | R44HL158318 | PP2A Anchoring Disruptor Therapy in Heart Failure | 000 | 1 | NIH | 3/21/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $3,197,499 ) |
| | 2023 | 2023 | CARDIAC RSK3 INHIBITORS, LLC | 24133 YOUNG COURT | LOS ALTOS | CA | 94024-5231 | SANTA CLARA | USA | R44HL167349 | RSK3 Anchoring Disruptor Therapy for Heart Failure | 000 | 1 | NIH | 9/14/2023 | $1,978,293 |
| | 2023 | 2023 | CARDIAC RSK3 INHIBITORS, LLC | 24133 YOUNG COURT | LOS ALTOS | CA | 94024-5231 | SANTA CLARA | USA | R44HL158318 | PP2A Anchoring Disruptor Therapy in Heart Failure | 000 | 3 | NIH | 8/12/2023 | $1,219,206 |
|
| Issue Date FY: 2022 ( Subtotal = $2,773,844 ) |
| | 2022 | 2022 | CARDIAC RSK3 INHIBITORS, LLC | 24133 YOUNG COURT | LOS ALTOS | CA | 94024-5231 | SANTA CLARA | USA | R44HL147631 | ShRNA-Based Targeting of mAKAPβ in Heart Failure | 003 | 3 | NIH | 5/27/2022 | $885,032 |
| | 2022 | 2022 | CARDIAC RSK3 INHIBITORS, LLC | 24133 YOUNG COURT | LOS ALTOS | CA | 94024-5231 | SANTA CLARA | USA | R44HL158318 | PP2A Anchoring Disruptor Therapy in Heart Failure | 002 | 2 | NIH | 8/25/2022 | $0 |
| | 2022 | 2022 | CARDIAC RSK3 INHIBITORS, LLC | 24133 YOUNG COURT | LOS ALTOS | CA | 94024-5231 | SANTA CLARA | USA | R44HL158318 | PP2A Anchoring Disruptor Therapy in Heart Failure | 001 | 2 | NIH | 8/19/2022 | $1,888,812 |
| | 2022 | 2021 | CARDIAC RSK3 INHIBITORS, LLC | 24133 YOUNG COURT | LOS ALTOS | CA | 94024-5231 | SANTA CLARA | USA | R44HL147631 | ShRNA-Based Targeting of mAKAPβ in Heart Failure | 001 | 2 | NIH | 2/1/2022 | $0 |
| | 2022 | 2021 | CARDIAC RSK3 INHIBITORS, LLC | 24133 YOUNG COURT | LOS ALTOS | CA | 94024-5231 | SANTA CLARA | USA | R44HL147631 | ShRNA-Based Targeting of mAKAPβ in Heart Failure | 002 | 2 | NIH | 2/8/2022 | $0 |
| | 2022 | 2021 | CARDIAC RSK3 INHIBITORS, LLC | 24133 YOUNG COURT | LOS ALTOS | CA | 94024-5231 | SANTA CLARA | USA | R44HL158318 | PP2A Anchoring Disruptor Therapy in Heart Failure | 000 | 1 | NIH | 12/14/2021 | $0 |
| | 2022 | 2019 | CARDIAC RSK3 INHIBITORS, LLC | 24133 YOUNG COURT | LOS ALTOS | CA | 94024-5231 | SANTA CLARA | USA | R44HL147631 | ShRNA-Based Targeting of mAKAPβ in Heart Failure | 000 | 1 | NIH | 1/27/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $2,198,913 ) |
| | 2021 | 2021 | CARDIAC RSK3 INHIBITORS, LLC | 24133 YOUNG COURT | LOS ALTOS | CA | 94024-5231 | SANTA CLARA | USA | R44HL158318 | PP2A Anchoring Disruptor Therapy in Heart Failure | 000 | 1 | NIH | 8/27/2021 | $436,929 |
| | 2021 | 2021 | CARDIAC RSK3 INHIBITORS, LLC | 24133 YOUNG COURT | LOS ALTOS | CA | 94024-5231 | SANTA CLARA | USA | R44HL147631 | ShRNA-Based Targeting of mAKAPβ in Heart Failure | 003 | 2 | NIH | 5/10/2021 | $1,761,984 |
| | 2021 | 2019 | CARDIAC RSK3 INHIBITORS, LLC | 24133 YOUNG COURT | LOS ALTOS | CA | 94024-5231 | SANTA CLARA | USA | R44HL147631 | ShRNA-Based Targeting of mAKAPβ in Heart Failure | 001 | 1 | NIH | 1/27/2021 | $0 |
| | 2021 | 2019 | CARDIAC RSK3 INHIBITORS, LLC | 24133 YOUNG COURT | LOS ALTOS | CA | 94024-5231 | SANTA CLARA | USA | R44HL147631 | ShRNA-Based Targeting of mAKAPβ in Heart Failure | 002 | 1 | NIH | 4/27/2021 | $0 |
| | 2021 | 2019 | CARDIAC RSK3 INHIBITORS, LLC | 24133 YOUNG COURT | LOS ALTOS | CA | 94024-5231 | SANTA CLARA | USA | R44HL147631 | ShRNA-Based Targeting of mAKAPβ in Heart Failure | 000 | 1 | NIH | 11/12/2020 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2019 | CARDIAC RSK3 INHIBITORS, LLC | 24133 YOUNG COURT | LOS ALTOS | CA | 94024-5231 | SANTA CLARA | USA | R44HL147631 | ShRNA-Based Targeting of mAKAPβ in Heart Failure | 000 | 1 | NIH | 11/22/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $332,445 ) |
| | 2019 | 2019 | CARDIAC RSK3 INHIBITORS, LLC | 24133 YOUNG COURT | LOS ALTOS | CA | 94024-5231 | SANTA CLARA | USA | R44HL147631 | ShRNA-Based Targeting of mAKAPβ in Heart Failure | 000 | 1 | NIH | 7/24/2019 | $332,445 |
|
|
